Last updated on August 2018

A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis


Brief description of study

A Phase 3b, single arm, open-label, multicenter study to evaluate the safety and to demonstrate the sustained virologic response 12 weeks post dosing (SVR12) rates of 8 weeks of treatment with the glecaprevir (GLE)/pibrentasvir (PIB) combination regimen to the historical SVR12 rate of 12 weeks of treatment with the GLE/PIB in treatment-nave adults with chronic HCV Genotype 1-6 infection and compensated cirrhosis.

Clinical Study Identifier: NCT03089944

Contact Investigators or Research Sites near you

Start Over

ABBVIE CALL CENTER

Tel Aviv Sourasky Medical Ctr /ID# 162185
Tel Aviv-Yafo, Israel
  Connect »

ABBVIE CALL CENTER

Sheba Medical Center /ID# 162028
Ramat Gan, Israel
2.78miles
  Connect »